Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : HOX Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Hox Therapeutics and Vernalis Announce a Drug Discovery Collaboration in Oncology
Details : Through collaboration, Vernalis will get access to the Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the oncology target.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : HOX Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Pierre Fabre
Deal Size : Undisclosed
Deal Type : Collaboration
Pierre Fabre Laboratories and Vernalis Announce a Drug Discovery Collaboration in Oncology
Details : Under the terms of the collaboration, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of multiple oncology targets and use fragment and structure-based methods to identify small molecules that modulate their acti...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Pierre Fabre
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Unison Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Vernalis will use its expertise in drug discovery to design small molecules against this particularly challenging target, which has long been considered to be undruggable.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Unison Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Ligand Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The new 3 years research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as part of the Vernalis Design Platform with the oncology expertise at Servier to enable to identify and enable new therapeutic targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 15, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Ligand Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ciforadenant
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2016
Lead Product(s) : Ciforadenant
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciforadenant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2014
Lead Product(s) : Ciforadenant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2012
Lead Product(s) : Ciforadenant
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2012
Lead Product(s) : Ciforadenant
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : V158866
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Ascending Dose Study of V158866 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 06, 2012
Lead Product(s) : V158866
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indantadol
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Manchester University NHS FT
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Open-Label Pilot Study of V3381 in Chronic Cough
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2011
Lead Product(s) : Indantadol
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Manchester University NHS FT
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
